Right Dose

Clinical studies with coxibs have shown that anti-cancer efficacy continues to increase as coxib doses rise above the approved and clinically accepted doses used for rheumatoid arthritis, osteoarthritis, or acute pain. These coxib doses approved for pain and inflammation are unable to achieve complete pharmacological suppression of the high levels of COX-2 activity in tumor cells and the tumor-immune microenvironment, as is necessary to afford good anti-cancer efficacy.

Euclicoxibs™ allow for safe use of the higher doses required for maximal COX-2 inhibition, biomarker suppression, and anti-cancer efficacy.